GIOTRIF® provides ≥3 years long-term response even with dose modification Read more about GIOTRIF® provides ≥3 years long-term response even with dose modification
GIOTRIF® maintains efficacy despite dose modification Read more about GIOTRIF® maintains efficacy despite dose modification
SEREAL||RealGiDo: Impact of GIOTRIF® dose adjustment in the real-world setting Read more about SEREAL||RealGiDo: Impact of GIOTRIF® dose adjustment in the real-world setting
SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies) Read more about SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies)
Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC Read more about Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC
SEREAL||GIOTRIF® followed by 3rd generation TKI in RESET study Read more about SEREAL||GIOTRIF® followed by 3rd generation TKI in RESET study
SEREAL||GioTag sequence may delay time to chemotherapy Read more about SEREAL||GioTag sequence may delay time to chemotherapy
